D A Calhoun

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. pmc Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report
    K Gaddam
    Division of Cardiovascular Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA
    J Hum Hypertens 24:532-7. 2010
  2. pmc Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort
    David A Calhoun
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, 430 BMR3, 1530 3rd Ave South, Birmingham, AL 35242
    Hypertension 63:451-8. 2014
  3. pmc Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Wake Disorders Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Curr Med Res Opin 29:901-10. 2013
  4. doi request reprint Hyperaldosteronism as a common cause of resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Disorders Clinic, University of Alabama at Birmingham, Birmingham, Alabama 35294 2180, USA
    Annu Rev Med 64:233-47. 2013
  5. pmc A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR
    Wei Feng
    Electrical and Computer Engineering Department, Auburn University, Auburn, AL 36849, USA
    J Cardiovasc Magn Reson 11:30. 2009
  6. ncbi request reprint Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
    David A Calhoun
    Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, AL 35294 0007, USA
    Chest 125:112-7. 2004
  7. ncbi request reprint Is there an unrecognized epidemic of primary aldosteronism? Pro
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham
    Hypertension 50:447-53; discussion 447-53. 2007
  8. ncbi request reprint Use of aldosterone antagonists in resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA
    Prog Cardiovasc Dis 48:387-96. 2006
  9. pmc The role of aldosteronism in causing obesity-related cardiovascular risk
    David A Calhoun
    University of Alabama at Birmingham, 35294 2180, USA
    Cardiol Clin 28:517-27. 2010
  10. ncbi request reprint Obstructive sleep apnea and hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Wake Disorders Center, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294 2180, USA
    Curr Hypertens Rep 12:189-95. 2010

Research Grants

Detail Information

Publications65

  1. pmc Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report
    K Gaddam
    Division of Cardiovascular Diseases, Ochsner Clinic Foundation, New Orleans, LA, USA
    J Hum Hypertens 24:532-7. 2010
    ..If confirmed in a randomized assessment, it will support aldosterone-mediated chronic fluid retention as an important mediator of OSA severity in patients with resistant hypertension...
  2. pmc Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort
    David A Calhoun
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, 430 BMR3, 1530 3rd Ave South, Birmingham, AL 35242
    Hypertension 63:451-8. 2014
    ..These data indicate that although resistant hypertension is relatively common among treated patients with hypertension, true antihypertensive treatment failure is rare. ..
  3. pmc Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Wake Disorders Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Curr Med Res Opin 29:901-10. 2013
    ....
  4. doi request reprint Hyperaldosteronism as a common cause of resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Disorders Clinic, University of Alabama at Birmingham, Birmingham, Alabama 35294 2180, USA
    Annu Rev Med 64:233-47. 2013
    ..Chlorthalidone is a potent, long-acting thiazide-like diuretic and should be used preferentially to treat resistant hypertension as it is superior to normally used doses of hydrochlorothiazide...
  5. pmc A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR
    Wei Feng
    Electrical and Computer Engineering Department, Auburn University, Auburn, AL 36849, USA
    J Cardiovasc Magn Reson 11:30. 2009
    ....
  6. ncbi request reprint Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea
    David A Calhoun
    Veterans Affairs Medical Center, University of Alabama at Birmingham, Birmingham, AL 35294 0007, USA
    Chest 125:112-7. 2004
    ..Having observed a high prevalence of OSA among hypertensive subjects with primary hyperaldosteronism, we hypothesized a possible association between sleep apnea and aldosterone excretion...
  7. ncbi request reprint Is there an unrecognized epidemic of primary aldosteronism? Pro
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham
    Hypertension 50:447-53; discussion 447-53. 2007
  8. ncbi request reprint Use of aldosterone antagonists in resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA
    Prog Cardiovasc Dis 48:387-96. 2006
    ..Both agents are generally well tolerated. Hyperkalemia is an uncommon complication of aldosterone antagonists, but it can occur; therefore, biochemical monitoring is necessary, particularly in high-risk patients...
  9. pmc The role of aldosteronism in causing obesity-related cardiovascular risk
    David A Calhoun
    University of Alabama at Birmingham, 35294 2180, USA
    Cardiol Clin 28:517-27. 2010
    ..Such a cause-and-effect situation would then provide the opportunity to reverse that risk with preferential use of aldosterone antagonists in obese patients...
  10. ncbi request reprint Obstructive sleep apnea and hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Wake Disorders Center, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294 2180, USA
    Curr Hypertens Rep 12:189-95. 2010
    ..We hypothesize that aldosterone excess worsens OSA by promoting accumulation of fluid in the neck, which then contributes to increased upper airway resistance...
  11. ncbi request reprint Aldosteronism and hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Sleep Wake Disorders Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin J Am Soc Nephrol 1:1039-45. 2006
    ..In a recent prospective analysis from the Framingham investigators, baseline serum aldosterone was strongly associated with development of hypertension during a 4-yr follow-up...
  12. ncbi request reprint Resistant or difficult-to-treat hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, Center for Sleep Wake Disorders, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Clin Hypertens (Greenwich) 8:181-6. 2006
    ..Recent data indicate that aldosterone antagonists may be effective when added to existing antihypertensive regimens even in the absence of primary aldosteronism...
  13. doi request reprint Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Circulation 124:1945-55. 2011
    ..LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may have benefit in the treatment of hypertension...
  14. doi request reprint Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial
    David A Calhoun
    Sleep Wake Disorders Center, University of Alabama at Birmingham, 35294, USA
    Hypertension 54:32-9. 2009
    ..In conclusion, this study demonstrates the efficacy/safety of treating moderate and severe hypertension with Aml/Val/HCTZ 10/320/25 mg...
  15. ncbi request reprint Hyperaldosteronism among black and white subjects with resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Ala, USA
    Hypertension 40:892-6. 2002
    ..The accuracy of these results is strengthened by having done suppression testing of all evaluated subjects...
  16. pmc Sleep and hypertension
    David A Calhoun
    Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 1150, USA
    Chest 138:434-43. 2010
    ..Additional prospective studies are needed to reconcile observational studies suggesting that OSA is a strong risk factor for hypertension with the modest antihypertensive effects of CPAP observed in intervention studies...
  17. ncbi request reprint Resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 520 ZRB, 703 South 19th Street, Birmingham, AL 35294, USA
    Curr Hypertens Rep 4:221-8. 2002
    ..Pharmacologic therapy should utilize combination therapy, including a long-acting diuretic...
  18. ncbi request reprint Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious rats
    D A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama, Birmingham 35294, USA
    J Hypertens 19:2025-9. 2001
    ..The current study was conducted to determine if angiotensin converting enzyme inhibitors likewise suppress cardiac sympathetic activation...
  19. ncbi request reprint Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats
    D A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA
    J Hypertens 17:507-12. 1999
    ..In a second experiment, we determined the effect of these drugs on arterial baroreflex control of lumbar sympathetic nerve activity...
  20. ncbi request reprint Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension
    David A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama Sleep Wake Disorders Center, University of Alabama at Birmingham, USA
    J Clin Hypertens (Greenwich) 9:19-24. 2007
    ..Risk of hyperkalemia is increased in patients with chronic kidney disease or diabetes, elderly patients, and patients already receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker...
  21. doi request reprint Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety
    David A Calhoun
    University of Alabama at Birmingham, Sleep Wake Disorders Center, 35294, USA
    Adv Ther 26:1012-23. 2009
    ..To elucidate the effects of time and baseline BP on the observed responses, exploratory analyses were performed...
  22. doi request reprint Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease
    R Pisoni
    Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC 29425, USA
    J Hum Hypertens 26:502-6. 2012
    ....
  23. ncbi request reprint Treatment of resistant hypertension
    M Czarina Acelajado
    Vascular Biology and Hypertension Program, University of Alabama, Birminham, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294 2041, USA
    Minerva Cardioangiol 57:787-812. 2009
    ..The purpose of this review was to discuss RH, its definition, recognition, evaluation and treatment...
  24. pmc Resistant hypertension, obstructive sleep apnoea and aldosterone
    T Dudenbostel
    Vascular Biology and Hypertension Program, Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Hum Hypertens 26:281-7. 2012
    ..We hypothesize that aldosterone excess worsens OSA by promoting accumulation of fluid within the neck, which then contributes to increased upper airway resistance...
  25. pmc Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension
    Carolina C Gonzaga
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, AL, USA
    J Clin Sleep Med 6:363-8. 2010
    ..This investigation examines the relationship between aldosterone status and OSA in patients with resistant hypertensive-with and without hyperaldosteronism...
  26. pmc Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study
    Krishna Gaddam
    Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
    Hypertension 55:1137-42. 2010
    ..In subjects with high aldosterone, mineralocorticoid receptor blockade induces a prominent diuretic effect compared with a greater vasodilatory effect in subjects with normal aldosterone status...
  27. ncbi request reprint Race, family history of hypertension, and sympathetic response to cold pressor testing
    D A Calhoun
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, USA
    Blood Press 6:209-13. 1997
    ..These results indicate that the greater sympathetic response to cold stress observed in normotensive African-Americans is true only of black subjects with a positive family history of hypertension...
  28. ncbi request reprint Primary aldosteronism: diagnostic and therapeutic considerations
    Mari K Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294, USA
    Curr Cardiol Rep 7:412-7. 2005
    ..Its specificity, however, is low such that a high ratio is suggestive of PA but must be confirmed by demonstration of high and autonomous secretion of aldosterone...
  29. ncbi request reprint Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy
    A R Carter
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Am J Physiol Cell Physiol 281:C1413-21. 2001
    ..These findings suggest that whole-cell patch clamp of peripheral blood lymphocytes can be used to identify accurately and rapidly hypertensive individuals who will respond to amiloride therapy...
  30. ncbi request reprint Managing the patient with hard-to-control hypertension
    S Oparil
    Division of Cardiovascular Disease, University of Alabama School of Medicine, Birmingham, USA
    Am Fam Physician 57:1007-14, 1019-20. 1998
    ..In many patients, these factors must be dealt with before blood pressure can be controlled...
  31. doi request reprint Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension
    David A Calhoun
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Curr Med Res Opin 24:2303-11. 2008
    ..This study evaluated the therapeutic efficacy and tolerability of initial treatment with the combination of valsartan and hydrochlorothiazide (HCTZ) compared with valsartan monotherapy in patients with severe hypertension...
  32. ncbi request reprint Resistant hypertension and hyperaldosteronism
    Carolina C Gonzaga
    Curr Hypertens Rep 10:496-503. 2008
    ..Recent studies demonstrate that mineralocorticoid receptor antagonists provide substantial antihypertensive benefit when added to multidrug regimens, even in patients without demonstrable aldosterone excess...
  33. doi request reprint Resistant hypertension: who and how to evaluate
    Maria Czarina Acelajado
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama 35294 2041, USA
    Curr Opin Cardiol 24:340-4. 2009
    ..We focus on important associations between resistant hypertension and primary aldosteronism and with obstructive sleep apnea...
  34. pmc Characterization and treatment of resistant hypertension
    Roberto Pisoni
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 115 Community Health Services Building, 933 19th Street South, Birmingham, AL 35294, USA
    Curr Cardiol Rep 11:407-13. 2009
    ..The addition of an aldosterone antagonist may further improve blood pressure control...
  35. ncbi request reprint Reduction of blood pressure in patients with treatment-resistant hypertension
    Maria Czarina Acelajado
    University of Alabama at Birmingham, 35294 2041, USA
    Expert Opin Pharmacother 10:2959-71. 2009
    ..Resistant hypertension is a common clinical problem, and patients with resistant hypertension have increased cardiovascular risk. It is a subset of the hypertensive population that is little studied and poorly characterized...
  36. doi request reprint Current options for the treatment of resistant hypertension
    Mustafa I Ahmed
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 1530 3rd Avenue South, Birmingham, AL 35294 2041, USA
    Expert Rev Cardiovasc Ther 7:1385-93. 2009
    ..Finally, when appropriate, specialist referral may facilitate blood pressure reduction and the ability to meet target blood pressure goals...
  37. doi request reprint Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment
    Maria Czarina Acelajado
    Department of Medicine, University of Alabama at Birmingham, 35294 2041, USA
    Cardiol Clin 28:639-54. 2010
    ....
  38. pmc Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion
    Krishna K Gaddam
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 933 19th St S, Community Health Services Bldg 115, Birmingham, AL 35294, USA
    Arch Intern Med 168:1159-64. 2008
    ..Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage...
  39. ncbi request reprint Resistant hypertension and aldosteronism
    Eduardo Pimenta
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 933 19th Street South, Room 115, Birmingham, AL 35294, USA
    Curr Hypertens Rep 9:353-9. 2007
    ..Recent studies indicate that the addition of spironolactone to standard treatment regimens induces significant blood pressure reduction in patients with resistant hypertension...
  40. ncbi request reprint Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension
    Eduardo Pimenta
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, AL, USA
    Hypertension 51:339-44. 2008
    ..003) was observed in subjects with high Ualdo but not in subjects with normal Ualdo (r=0.18; P value not significant). These results suggest that aldosterone excess and high dietary salt combine to increase urinary protein excretion...
  41. ncbi request reprint Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization
    Raed A Aqel
    Birmingham s Veterans Affair Medical Center, Division of Cardiovascular Disease, Birmingham, Alabama 35233, USA
    J Hypertens 21:1157-62. 2003
    ..The goal of this study is to determine the prevalence and predictors of renal artery stenosis in hypertensive veterans referred for coronary angiography...
  42. ncbi request reprint Efficacy of low-dose spironolactone in subjects with resistant hypertension
    Mari Konishi Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am J Hypertens 16:925-30. 2003
    ..Previous reports have demonstrated the antihypertensive efficacy of high doses of spironolactone in subjects with primary aldosteronism and, to a lesser degree, subjects with resistant hypertension...
  43. ncbi request reprint Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism
    Mari K Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, USA
    Circulation 109:2857-61. 2004
    ....
  44. ncbi request reprint Aldosterone antagonism: an emerging strategy for effective blood pressure lowering
    Monique N Pratt-Ubunama
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 933 19th Street South, Room 115, Birmingham, AL 35294, USA
    Curr Hypertens Rep 7:186-92. 2005
    ..With recent demonstrations of benefit in multiple segments of the hypertensive population, aldosterone antagonists represent emerging opportunity for controlling high blood pressure...
  45. ncbi request reprint Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension
    Mari K Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am J Hypertens 18:805-12. 2005
    ..Prior determinations of the validity of the ARR had been generally limited to subjects that could be withdrawn from antihypertensive therapy and to non-African American subjects...
  46. ncbi request reprint Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension
    Krishna K Gaddam
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 115 Community Health Services Building, 933 19 Street South, Birmingham, AL 35294, USA
    Expert Rev Cardiovasc Ther 4:353-9. 2006
    ..These agents are generally well tolerated. Hyperkalemia is an uncommon complication of aldosterone antagonists, but it can occur. Therefore, biochemical monitoring is necessary, particularly in high-risk patients...
  47. ncbi request reprint Primary aldosteronism: diagnosis and treatment
    Eduardo Pimenta
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 933 19th Street South, Birmingham, AL 35294, USA
    J Clin Hypertens (Greenwich) 8:887-93. 2006
    ....
  48. ncbi request reprint Use of aldosterone antagonists in resistant hypertension
    Mari K Nishizaka
    University of Alabama at Birmingham, 115 CHSB 19th, 933 South 19th Street, Birmingham, AL 35294, USA
    J Clin Hypertens (Greenwich) 6:458-60. 2004
  49. ncbi request reprint Aldosterone excess and resistance to 24-h blood pressure control
    Eduardo Pimenta
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Hypertens 25:2131-7. 2007
    ..Aldosterone excess has been reported to be a common cause of resistant hypertension. To what degree this represents true treatment resistance is unknown...
  50. ncbi request reprint Mechanisms and treatment of resistant hypertension
    Eduardo Pimenta
    Departamento de Hipertensão Arterial e Nefrologia, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, SP, Brasil
    Arq Bras Cardiol 88:683-92. 2007
  51. ncbi request reprint Drugs targeting the renin-angiotensin-aldosterone system
    Mohammad Amin Zaman
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Nat Rev Drug Discov 1:621-36. 2002
    ....
  52. ncbi request reprint Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension
    Monique N Pratt-Ubunama
    Vascular Biology and Hypertension Program, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA
    Chest 131:453-9. 2007
    ..This study relates plasma aldosterone and renin levels to OSA severity in subjects with resistant hypertension, and in those with equally severe OSA but without resistant hypertension serving as control subjects...
  53. ncbi request reprint Evaluation of low-dose endotoxin administration during pregnancy as a model of preeclampsia
    Y Sakawi
    Department of Anesthesiology, University of Alabama at Birmingham, 35233 6810, USA
    Anesthesiology 93:1446-55. 2000
    ..The authors tested the hypothesis that administration of low-dose endotoxin to pregnant rats mimics the signs of preeclampsia in humans and that *NO and *NO-derived species play a role in that animal model...
  54. ncbi request reprint The role of aldosterone antagonists in the management of resistant hypertension
    Mari K Nishizaka
    Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 430 BMR2, 1530 3rd Avenue South, Birmingham, AL 35294 2180, USA
    Curr Hypertens Rep 7:343-7. 2005
    ....
  55. ncbi request reprint The calcium antagonists in the 1990s. An overview
    S Oparil
    Department of Medicine, University of Alabama, Birmingham 35294
    Am J Hypertens 4:396S-405S. 1991
    ..The potential antiatherosclerotic and cardio-, neuro-, and renoprotective effects of the calcium antagonists, coupled with their lack of adverse metabolic effects, have defined an expanding therapeutic role for these agents in the 1990s...
  56. ncbi request reprint Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis
    Bret L Hicken
    Department of Psychology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Genet Test 8:90-7. 2004
    ..In the present hemochromatosis patients, few reported that HFE genotyping was accompanied by negative psychosocial outcomes...
  57. ncbi request reprint Pathogenesis of hypertension
    Suzanne Oparil
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Ann Intern Med 139:761-76. 2003
  58. ncbi request reprint Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTAT
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    J Clin Hypertens (Greenwich) 10:450-8. 2008
    ..This study suggests that in the management of hypertension, utilizing an angiotensin receptor blocker/diuretic combination was more effective in lowering BP and achieving BP goals when compared with increasing the dose of the diuretic...
  59. ncbi request reprint Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy
    Theodore L Goodfriend
    Research Service, William S Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705, USA
    Hypertension 43:518-24. 2004
    ....
  60. ncbi request reprint The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy
    Murray Epstein
    Professor of Medicine, Nephrology Section, VA Medical Center, Miami, FL 33125, USA
    Curr Hypertens Rep 9:98-105. 2007
    ..Consequently, aldosterone blockade constitutes an effective intervention for treating resistant hypertension...
  61. ncbi request reprint Aldosterone, dietary salt, and renal disease
    Eduardo Pimenta
    Hypertension 48:209-10. 2006
  62. ncbi request reprint Aldosterone and cardiovascular disease: smoke and fire
    David A Calhoun
    Circulation 114:2572-4. 2006
  63. ncbi request reprint 2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice?
    Carolina C Gonzaga
    Pol Arch Med Wewn 118:396-7. 2008
  64. ncbi request reprint Weight gain and hypertension: the chicken-egg question revisited
    David A Calhoun
    J Hypertens 22:1869-71. 2004
  65. ncbi request reprint Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries
    Mari K Nishizaka
    J Hypertens 24:435-6. 2006

Research Grants7

  1. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2006
    ..Subjects found not to have OSA will serve as controls. ..
  2. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2004
    ..Subjects found not to have OSA will serve as controls. ..
  3. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2005
    ..Subjects found not to have OSA will serve as controls. ..
  4. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2007
    ..Subjects found not to have OSA will serve as controls. ..
  5. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David Calhoun; Fiscal Year: 2009
    ..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..
  6. Etiology of Sleep Apnea-Related Hyperaldosteronism
    David A Calhoun; Fiscal Year: 2010
    ..Both possibilities would significantly lower cardiovascular risk in patients with difficult-to-control hypertension. ..